144 related articles for article (PubMed ID: 38846741)
1. A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria.
Du W; Mei L
Res Pract Thromb Haemost; 2024 May; 8(4):102435. PubMed ID: 38846741
[TBL] [Abstract][Full Text] [Related]
2. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong RSM
Ther Adv Hematol; 2022; 13():20406207221114673. PubMed ID: 35923770
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
6. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Xu B
Clin Exp Med; 2023 Jul; 23(3):717-726. PubMed ID: 35441351
[TBL] [Abstract][Full Text] [Related]
7. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis.
Sharma R; Keyzner A; Liu J; Bradley T; Allen SL
Leuk Res Rep; 2015; 4(1):36-8. PubMed ID: 26052501
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
9. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
10. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
Miyasaka N; Miura O; Kawaguchi T; Arima N; Morishita E; Usuki K; Morita Y; Nishiwaki K; Ninomiya H; Gotoh A; Imashuku S; Urabe A; Shichishima T; Nishimura J; Kanakura Y
Int J Hematol; 2016 Jun; 103(6):703-12. PubMed ID: 26857155
[TBL] [Abstract][Full Text] [Related]
12. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
[TBL] [Abstract][Full Text] [Related]
17. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.
de Latour RP; Szer J; Weitz IC; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro CM; Nishimori H; Ajayi T; Al-Adhami M; Deschatelets P; Francois C; Grossi F; Risitano AM; Hillmen P
Lancet Haematol; 2022 Sep; 9(9):e648-e659. PubMed ID: 36055332
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment.
Fishman J; Anderson S; Talbird SE; Dingli D
Hematol Rep; 2023 Oct; 15(4):578-591. PubMed ID: 37873795
[TBL] [Abstract][Full Text] [Related]
19. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.
Griffin M; Kelly RJ; Panse J; de Castro C; Szer J; Horneff R; Tan L; Yeh M; Peffault de Latour R
Blood Adv; 2024 Apr; 8(7):1776-1786. PubMed ID: 38315872
[TBL] [Abstract][Full Text] [Related]
20. Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report.
Fassett MJ; Hernandez Lopez AL
Case Rep Womens Health; 2021 Apr; 30():e00294. PubMed ID: 33665137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
